Bristol-Myers Squibb Co.'s surprise announcement that its Phase III CheckMate 227 first-line lung cancer study succeeded, but in a subset analysis that had not been prospectively defined, left one burning question – does the company have enough to file for approval? Management suggests the answer is yes, but some leading analysts have doubts.
The CheckMate 227 study is a multi-arm trial evaluating Bristol's PD-1 inhibitor Opdivo (nivolumab) with its CTLA-4 inhibitor Yervoy (ipilimumab)...






